Flexion Selects First Four Programs And Gets $9 Million From Pfizer Venture Fund
This article was originally published in The Pink Sheet Daily
Executive Summary
Modeled on Lilly's Chorus unit, Flexion purports to bring candidates to proof-of-concept quicker and cheaper than a Big Pharma typically can.
You may also be interested in...
Flexion’s Slow-Release Steroid Now On Faster Track With FDA
Following guidance from the agency on injectable osteoarthritis drug FX006, Flexion plans to file first with single-dose studies instead of waiting for longer-term data for repeated doses. This will speed up initial Phase III work by one year, the firm says.
Asset Finance Funds Aim for Pharma Cash, Partnerships
Like many of its drug-industry brethren, Bayer Healthcare AG says it's ready to find good homes for the drug candidates it can't develop itself
Asset Finance Funds Aim for Pharma Cash, Partnerships
Like many of its drug-industry brethren, Bayer Healthcare AG says it's ready to find good homes for the drug candidates it can't develop itself